1. Siskind, D, Siskind, V, Kisely, S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62: 772–777.
Google Scholar | SAGE Journals | ISI2. Chung, C, Remington, G. Predictors and markers of clozapine response. Psychopharmacology 2005; 179: 317–335.
Google Scholar | Crossref | Medline3. Remington, G, Agid, O, Foussias, G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology 2013; 225: 505–518.
Google Scholar | Crossref | Medline | ISI4. Stark, A, Scott, J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry 2012; 46: 816–825.
Google Scholar | SAGE Journals | ISI5. Miller, DD, Fleming, F, Holman, TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55(Suppl. B): 117–121.
Google Scholar | Medline | ISI6. Perry, PJ, Miller, DD, Arndt, SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231–235.
Google Scholar | Medline | ISI7. Schulte, P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42: 607–618.
Google Scholar | Crossref | Medline | ISI8. Spina, E, Avenoso, A, Facciolà, G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83–89.
Google Scholar | Crossref | Medline | ISI9. Hiemke, C, Bergemann, N, Clement, HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62.
Google Scholar | Crossref | Medline10. Mauri, M, Volonteri, LS, Fiorentini, A, et al. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res 2004; 66: 197–198.
Google Scholar | Crossref | Medline | ISI11. Wong, JO-Y, Leung, SP, Mak, T, et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 251–264.
Google Scholar | Crossref | Medline | ISI12. Yada, Y, Kitagawa, K, Sakamoto, S, et al. The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. Acta Psychiatr Scand 2021; 143: 227–237.
Google Scholar | Crossref | Medline13. Jääskeläinen, E, Juola, P, Hirvonen, N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39: 1296–1306.
Google Scholar | Crossref | Medline | ISI14. Van Eck, RM, Burger, TJ, Vellinga, A, et al. The relationship between clinical and personal recovery in patients with Schizophrenia spectrum disorders: a systematic review and meta-analysis. Schizophr Bull 2018; 44: 631–642.
Google Scholar | Crossref | Medline15. Phahladira, L, Luckhoff, HK, Asmal, L, et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophr 2020; 6: 2.
Google Scholar | Crossref | Medline16. Olagunju, AT, Clark, SR, Baune, BT. Clozapine and psychosocial function in schizophrenia: a systematic review and meta-analysis. CNS Drugs 2018; 32: 1011–1023.
Google Scholar | Crossref | Medline17. Davies, MA, Compton-Toth, BA, Hufeisen, SJ, et al. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? Psychopharmacology 2005; 178: 451–460.
Google Scholar | Crossref | Medline | ISI18. Schoretsanitis, G, Kane, JM, Ruan, C-J, et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 2019; 12: 603–621.
Google Scholar | Crossref | Medline19. Weiner, DM, Meltzer, HY, Veinbergs, I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004; 177: 207–216.
Google Scholar | Crossref | Medline | ISI20. Costa-Dookhan, KA, Agarwal, SM, Chintoh, A, et al. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. Expert Opin Drug Saf 2020; 19: 43–57.
Google Scholar | Crossref | Medline21. Couchman, L, Morgan, PE, Spencer, EP, et al. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010; 32: 438–447.
Google Scholar | Crossref | Medline | ISI22. Meltzer, HY. Attention must be paid: the association of plasma clozapine/NDMC ratio with working memory. Am J Psychiatry 2015; 172: 502–504.
Google Scholar | Crossref | Medline | ISI23. Krivoy, A, Joyce, D, Tracy, D, et al. Real-world outcomes in the management of refractory psychosis. J Clin Psychiatry 2019; 80: 18m12716.
Google Scholar | Crossref | Medline24. Lee, SW, Kielhofner, G, Morley, M, et al. Impact of using the model of human occupation: a survey of occupational therapy mental health practitioners’ perceptions. Scand J Occup Ther 2012; 19: 450–456.
Google Scholar | Crossref | Medline25. Parkinson, S, Chester, A, Cratchley, S, et al. Application of the Model of Human Occupation Screening Tool (MOHOST assessment) in an acute psychiatric setting. Occup Ther Health Care 2008; 22: 63–75.
Google Scholar | Crossref | Medline26. Sarkar, SN, Tracy, DK, Fernandez, M-JM, et al. Unheard voices: outcomes of tertiary care for treatment-refractory psychosis. Psychiatr Bull 2014; 38: 71–74.
Google Scholar | Crossref27. McGuffin, P, Farmer, A, Harvey, I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764–770.
Google Scholar | Crossref | Medline28. Brittain, PJ, Stahl, D, Rucker, J, et al. A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients. Int J Methods Psychiatr Res 2013; 22: 110–137.
Google Scholar | Crossref | Medline | ISI29. Vogeser, M, Seger, C. A decade of HPLC-MS/MS in the routine clinical laboratory–goals for further developments. Clin Biochem 2008; 41: 649–662.
Google Scholar | Crossref | Medline | ISI30. Molins, C, Carceller-Sindreu, M, Navarro, H, et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res 2017; 258: 153–157.
Google Scholar | Crossref | Medline31. Kronig, MH, Munne, RA, Szymanski, S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995; 152: 179–182.
Google Scholar | Crossref | Medline | ISI32. Xiang, Y-Q, Zhang, Z-J, Weng, Y-Z, et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 2006; 83: 201–210.
Google Scholar | Crossref | Medline | ISI33. Farde, L, Nordström, AL, Wiesel, FA, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538–544.
Google Scholar | Crossref | Medline34. Meltzer, HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989; 99: S18–S27.
Google Scholar | Crossref35. Kapur, S, Zipursky, RB, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286–293.
Google Scholar | Medline | ISI36. Swartz, MS, Perkins, DO, Stroup, TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428–436.
Google Scholar | Crossref | Medline | ISI